他氟前列素(Tafluprost) - 药物靶点：PGF2α_在研适应症：开角型青光眼，青光眼，高眼压症_专利_临床

Comparison Between the Effect of Latanoprost 0.005%, Travoprost 0.004% and Tafluprost 0.0015% on Diurnal Intraocular Pressure Fluctuation in Patients Having Primary Open-angle Glaucoma

Elevated IOP is a key risk factor for the progression of glaucoma. IOP is subjected to diurnal fluctuation in healthy individuals and higher fluctuation in POAG . So, once-daily antiglaucoma drugs must have consistent efficacy throughout the day. Prostaglandin analogues (PGAs) have become the first-line drops for medical treatment of glaucoma worldwide. In our study, we compare between the efficacy and tolerability of Latanoprost 0.005%, Travoprost 0.004% and Tafluprost 0.0015% on diurnal IOP fluctuation in patients having POAG, IOP fluctuation was assessed before treatment , then 2 weeks and 6 weeks after. A comparable and significant reduction in IOP fluctuation occurred in the 3 groups. Side effects were mild and tolerable.

开始日期2019-06-01

申办/合作机构

Qasr El Eyni Hospital

NCT03822559

/ Completed临床3期

A Randomized, Double-masked, Controlled Parallel Group, Multi-center Study of DE-111A (Fixed Dose Combination of Tafluprost and Timolol Eye Drops) on the Treatment of Open Angle Glaucoma or Ocular Hypertension (With Tafluprost Eye Drops as a Comparator)

The objective of this study is to investigate whether the IOP (intraocular pressure) -lowering effect of DE-111A (preservative-free fixed dose combination of 0.0015% tafluprost and 0.5% timolol eye drops, administered one drop a time, once daily for 3 months) is superior to the monotherapy of tafluprost 0.0015% eye drops administered one drop a time, once daily for 3 months) in subjects with open-angle glaucoma or ocular hypertension in China as well as comparison of safety.

开始日期2019-01-20

申办/合作机构

Santen Pharmaceutical Co., Ltd.

100 项与他氟前列素相关的临床结果

登录后查看更多信息

100 项与他氟前列素相关的转化医学

登录后查看更多信息

100 项与他氟前列素相关的专利（医药）

登录后查看更多信息

360

项与他氟前列素相关的文献（医药）

2025-08-01·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

HPLC method for detecting prostaglandin F2α analogs in cosmetics: Optimization for chromatographic separation and sample preparation

Article

作者: Sung, Min Kyung ; Kim, Hyun-Kyung ; Shin, Eun Jin ; Kim, Hyung Soo ; Woo, In Suk ; Han, Kyoung-Moon ; Kim, You Kyung

Some prostaglandin F_2α (PGF_2α) analogs, including bimatoprost and tafluprost, are pharmaceutical substances known to cause specific abnormal reactions that promote eyelash growth. However, research on the simultaneous analysis of multiple PGF_2α analogs using HPLC-UV or DAD techniques is limited. In this study, a high-performance liquid chromatography (HPLC) method was developed for the simultaneous analysis of 11 PGF_2α analogs, optimizing both the analytical column and sample preparation method. Five columns with varying particle sizes, lengths, and packing types were compared to select the optimal analytical column. The separation efficiency of the columns was confirmed by comparing their chromatographic parameters, including retention time, resolution, number of theoretical plates, and height equivalent to a theoretical plate. Solid-phase extraction (SPE) was used to pretreat cosmetic samples, and the washing solvent and cartridge type for the SPE process were optimized. The established HPLC method was validated in terms of linearity, limits of detection and quantification, recovery, accuracy, and precision. The verified analytical method was applied to eyelash serums currently available in the market, and norbimatoprost was detected in one product. The HPLC method proposed in this study may help prevent the distribution of cosmetics containing illegal PGF_2α analogs.

2025-01-02·Cutaneous and Ocular Toxicology

Changes in prostaglandin-associated periorbital syndrome: a self-controlled and prospective study

Article

作者: Li, Wenman ; Tang, Jing ; Li, Ni ; Chen, Sijie ; Lv, Zhiqing ; Chen, Xiaoming

INTRODUCTION:

In this study, we aimed to investigate the incidence of objective and subjective indicators of the prostaglandin-associated periorbital syndrome (PAPS) after continuous instillation of topical prostaglandin analogues (PGAs) in primary open-angle glaucoma or ocular hypertension patients.

METHODS:

A self-controlled and prospective study of PGA instillation was performed in patients (n = 55) with primary open-angle glaucoma or ocular hypertension. Bilateral instillation of bimatoprost, travoprost, latanoprost, or tafluprost was conducted (treatment, 3-6 months). The objective indicators recorded included interpupillary distance (IPD) and exophthalmos; subjective indicators were assessed via colour pictures of the periocular area. Data from before the administration of medication served as controls. Posttreatment changes in IPD, exophthalmos, deepening of the upper eyelid sulcus, periorbital hyperpigmentation and eyelash growth were analysed.

RESULTS:

Compared with those before treatment, the interpupillary distance (IPD) differed from the baseline value at 1 month after treatment (P < 0.0001), and the exophthalmos only significantly differed from the baseline value at month 3 (P = 0.0005). Visible periorbital changes at 1, 3, and 6 months after treatment were assessed, and the incidence of eyelash growth and thickening was 7.27%, 45.45% and 66.67%, respectively. The incidence of periorbital hyperpigmentation was 7.2%, 18.18% and 33.33%, respectively. The incidence of upper-eyelid sulcus deepening was 3.64%, 7.27% and 16.27%, respectively. Bimatoprost had the highest incidence of PAPS, followed by travoprost and tafluprost, and latanoprost had the lowest incidence after three months of treatment in the between-group comparison.

CONCLUSION:

As an objective index to evaluate PAPS, the change of IPD was more obvious than the exophthalmos. Visible periorbital changes gradually appeared after three months of medication. Bimatoprost caused the most severe PAPS, and latanoprost caused the least severe PAPS.

TRIAL REGISTRATION:

The study was registered at www.chictr.org.cn on 15 April 2021, under the identifier ChiCTR2100045465.

2025-01-01·JOURNAL OF CHROMATOGRAPHY A

Green extraction of prostaglandin analogs in cosmetics using deep eutectic solvents and detection via LC-MS/MS

Article

作者: Park, Chae Gyeong ; Woo, In Suk ; Kim, You Kyung ; Han, Kyoung-Moon ; Choi, Jang Duck ; Kim, Aeseul ; Son, Kyung Hun

Prostaglandin analogs (bimatoprost, travoprost, tafluprost, etc.) have similar effects to prostaglandins and are effective drugs for treating glaucoma. These compounds exhibit abnormal reactions such as causing eyelash growth, with several cases being reported of people purchasing them to increase eyelash growth; however, some cases have reported side effects such as pigmentation and dry eyes. In the Republic of Korea, cosmetics are not medicines for treating diseases; therefore, cosmetics cannot contain drugs or have labels that could mislead people. However, there are cases in which products claim to elongate and enrich eyelashes. Concerns about the abnormal reactions of these products are constantly growing, and the absence of analytical methods for illicit compounds (prostaglandins and their analogs) in cosmetics (eyelash growth serums) renders monitoring challenging. Accordingly, in this study, we sought to develop an LC-MS/MS method for facile and fast analysis of compounds illegally mixed into eyelash growth serums. Green analytical chemistry has recently emerged because of environmental concerns. In line with this trend, we developed an optimal method by comparing the methods mainly used in cosmetic pretreatment (solvent extraction, QuEChERS, and solid phase extraction) with a method using deep eutectic solvents (DESs), which is an eco-friendly solvent. As a result of validation according to the International Conference on Harmonization guidelines, the limit of detection was 0.20-9.34 ng/mL, and the limit of quantification was 0.60-28.31 ng/mL. Recovery, linearity, precision, and accuracy were within acceptable ranges. Additionally, using the Analytical GREEnness calculator and complex green analytical procedure index tools, we confirmed that the method using the DES was greener than the other methods. In this study, we developed an analytical method for illicit compounds contained in eyelash growth serums, offering an eco-friendly approach for the prevention of the distribution of illegal cosmetics.

71

项与他氟前列素相关的新闻（医药）

2025-04-07

·GBIHealth

14.18亿美元！礼来获Sangamo旗下AAV衣壳用于开发基因治疗药物

药械追踪No.1 / AZ/第一三共Enhertu欧盟适应证扩大至HR+/HER2低表达或超低表达乳腺癌2025年4月7日，阿斯利康和第一三共联合宣布，注射用德曲妥珠单抗（商品名：Enhertu/优赫得）已获欧盟委员会（EC）批准新适应证，单药用于既往接受过至少一次内分泌治疗且被认为不适合继续接受内分泌治疗的不可切除或转移性激素受体（HR）阳性、HER2低表达或HER2超低表达乳腺癌成人患者。此次获批使Enhertu在HR+/HER2低表达乳腺癌的治疗线提前，并将适用患者群体扩大至涵盖HER2超低表达患者。Enhertu是阿斯利康和第一三共合作开发和商业化的HER2靶向抗体偶联药物（ADC），已在全球多个市场获批用于HER2阳性乳腺癌、非小细胞肺癌（NSCLC）、胃或胃食管结合部腺癌（GC/GEJC）等实体瘤适应证。Enhertu本次获欧盟批准扩展适应证主要基于III期试验DESTINY-Breast06的积极结果，该研究证实，与化疗相比，Enhertu使疾病进展或死亡风险降低了38%，并显著改善了患者的无进展生存期（mPFS：13.2个月 vs 8.1个月）。->点击文末阅读原文，解锁完整双语新闻No.2 / 参天制药青光眼滴眼液Tapcom在华获批2025年4月4日，日本参天制药株式会社（以下简称“参天制药”）宣布，旗下Tapcom（他氟前列素/噻吗洛尔复合滴眼液，研发代号：STN1011101）已获中国国家药品监督管理局（NMPA）批准。Tapcom为不含防腐剂的固定复方滴眼液，含0.0015%他氟前列素和0.5%马来酸噻吗洛尔；这2种对房水动力学有不同作用机制的有效成份均能降低眼压。Tapcom适用于降低开角型青光眼或高眼压症患者的眼压，为局部使用β受体阻滞剂或前列腺素衍生物单药治疗未能达到目标眼压的患者提供新的治疗选择，同时也适用于长期局部使用青光眼药物期间可能受益于不含防腐剂滴眼液的患者。->点击文末阅读原文，解锁完整双语新闻企业动态No.1 / ABL Bio与GSK达成超20亿英镑合作，开发神经退行性疾病创新药物2025年4月6日，韩国临床阶段生物技术公司ABL Bio Inc.（KOSDAQ：298380）宣布与葛兰素史克（GSK）达成全球授权协议，授权GSK利用ABL Bio的血脑屏障（BBB）穿梭平台Grabody-B，开发治疗神经退行性疾病的创新药物。该协议针对包括抗体、多核苷酸或寡核苷酸（如siRNA和ASOs）在内的多种治疗模式，双方将合作开发针对全新靶点的多个项目，以满足神经退行性疾病患者尚未被满足的重大医疗需求。根据协议条款，ABL Bio将获得高达7710万英镑的预付款及近期款项，包括3850万英镑的即时预付款、研究里程碑付款及潜在项目扩展费用。基于多个潜在项目，ABL Bio总共将有资格获得高达20.75亿英镑的研究、开发、监管审批及商业化里程碑付款。若产品成功商业化，ABL Bio还将获得净销售额的分级特许权使用费。作为协议的一部分，ABL Bio将向GSK转让Grabody-B相关技术和专有技术，而GSK将负责临床前和临床开发、生产及商业化。->点击文末阅读原文，解锁完整双语新闻No.2 / 14.18亿美元！礼来获Sangamo旗下AAV衣壳用于开发基因治疗药物2025年4月3日，Sangamo Therapeutics（Nasdaq：SGMO）宣布，已与礼来（NYSE：LLY）达成许可协议，授予礼来公司Sangamo创新的专有嗜神经性腺相关病毒（AAV）衣壳STAC-BBB全球独家使用权，该衣壳已在非人类灵长类动物中显示出强大的血脑屏障穿透能力和神经元转导能力。根据协议，礼来可使用STAC-BBB衣壳用于一个初始靶点，并在支付额外的许可靶点费用后，有权增加多达四个额外靶点，以提供其静脉注射给药的基因治疗药物，用于治疗某些中枢神经系统疾病。Sangamo负责完成与STAC-BBB衣壳相关的技术转移。礼来公司负责所有研究、临床前和临床开发、监管互动、生产以及任何由此产生的基因治疗产品的全球商业化。Sangamo将从礼来公司获得1800万美元的前期许可费，并有资格在五个潜在神经疾病靶点上获得高达14亿美元的额外许可靶点费用和里程碑付款，以及按这些产品的潜在净销售额分层的特许权使用费，但需根据某些特定条款进行相应减免。->点击文末阅读原文，解锁完整双语新闻No.3 / 百济神州终止欧司珀利单抗肺癌潜在疗法临床开发项2025年4月3日，百济神州（Nasdaq：ONC；6160.HK；688235.SH）宣布，将终止抗TIGIT抗体欧司珀利单抗（BGB-A1217）作为肺癌潜在治疗方法的临床开发项目。依据预先计划的无效性分析结果，独立数据监查委员会建议终止正在进行的3期AdvanTIG-302试验（NCT04746924）。试验的总体有效性和安全性数据评估表明，该研究或难以达到总生存期主要终点。但同时，未发现新的安全信号。经慎重考虑，公司决定终止该试验。欧司珀利单抗是一款TIGIT单抗，2021年12月，诺华曾斥资28.95亿美元引进该药，但该交易于2023年7月终止。->点击文末阅读原文，解锁完整双语新闻全球医疗情报领导者解锁隐藏在数据中的商业潜力关于 G B I”自从2002年成立以来，GBI始终以技术为驱动，为药企、器械及行业相关服务商提供贯穿生命周期的全球药品市场竞争数据、全球行业资讯、HCPs洞察、全国医疗器械数据等商业信息与洞察，助力企业在进行战略布局和决策时，脱颖而出。历经20余年的深耕细作GBI已成为95%以上跨国药企、国内头部药企、咨询与投资机构等医疗圈灯塔用户值得信赖的长期合作伙伴。联系我们投稿 | 发稿 | 媒体合作▶ xujingou@baidu.com数据库 | 咨询服务 | 资讯追踪▶ 点击左下“阅读原文”完成表单填写点击阅读原文，解锁完整双语新闻

引进/卖出临床3期寡核苷酸抗体药物偶联物siRNA

2025-04-07

·Pharmaceutical Technology

China’s NMPA authorises Santen’s glaucoma treatment application

The eyedrop is an option for those who are benefitting from preservative-free eye drops. Credit: Andrey Sayfutdinov/Shutterstock. China’s National Medical Products Administration (NMPA) has approved the marketing authorisation application of Santen Pharmaceutical’s Tapcom to treat individuals with open-angle glaucoma or ocular hypertension. This fixed-combination eye drop comprising tafluprost 0.0015% and timolol 0.5% is designed to lower intraocular pressure (IOP) for individuals with this condition. Glaucoma damages the optic nerve and results in visual field loss. The eye drop offers a therapeutic alternative for individuals whose topical beta-blockers or prostaglandin derivatives monotherapies have not achieved target IOP. It is also an option for those who are benefitting from preservative-free eye drops in prolonged topical usage of glaucoma medication. Tapcom is the country’s first preservative-free ophthalmic combo formulation to include a first-line prostaglandin derivative. Its two active ingredients, tafluprost and timolol maleate, work through different mechanisms to reduce IOP. Tafluprost acid, the active metabolite of tafluprost, is a prostanoid FP receptor agonist that promotes aqueous humour outflow. A nonselective β-receptor inhibitor, timolol maleate, decreases the production of aqueous humour. Tapcom has gained approval in 40 countries and regions, including Asia and Europe. Santen Pharmaceutical chief medical officer Peter Sallstig stated: “Glaucoma remains the leading cause of irreversible blindness worldwide, deeply impacting the quality of life of many patients. “Therefore, Santen has prioritised glaucoma as a key therapeutic focus, dedicating ourselves to the development of treatments that meet patients’ needs and the delivery of high-quality ophthalmic drugs. The approval of Tapcom in China represents a significant milestone, offering new treatment options for Chinese glaucoma patients and advancing the field of glaucoma care.” In November 2024, the company and Arctic Vision signed a commercial partnership agreement for the ARVN001 suprachoroidal injectable suspension for uveitic macular oedema and other ocular conditions.

上市批准

2025-03-31

·Pharma CMC

创新药 “爆发” 获批！今日85个上市申请获NMPA批准

刚刚，NMPA发布2025年03月31日药品批准证明文件送达信息，本批次共有85个受理号获批，均为上市申请，其中多款创新药获批：此前，NMPA公告过的：宜昌东阳光长江药业的艾考磷布韦片获批上市，用于与磷酸萘坦司韦胶囊联用，治疗初治或干扰素经治的基因1、2、3、6型成人慢性丙型肝炎病毒（HCV）感染，可合并或不合并代偿性肝硬化。江西科睿药业申报的玛舒拉沙韦片获批上市，用于既往健康的12岁及以上青少年和成人单纯性甲型和乙型流感患者的治疗，不包括存在流感相关并发症高风险的患者。恒瑞医药的硫酸艾玛昔替尼片获批上市，用于治疗对一种或多种TNF抑制剂疗效不佳或不耐受的活动性强直性脊柱炎成人患者。此外，参天制药的他氟噻吗滴眼液获批上市，推测适应症为：用于降低开角型青光眼或高眼压症成年患者的眼压（IOP），用于对局部单独使用β-受体阻滞剂或前列腺素衍生物疗效不佳而需要联合治疗的患者。他氟噻吗滴眼液是不含防腐剂的0.0015%他氟前列素和0.5%马来酸噻吗洛尔固定剂量复方滴眼液，含有两种对房水动力学有不同作用机制的有效成分，每日滴眼1次即可达到与联合用药相同的有效性和安全性。罗氏的奥瑞利珠单抗注射液（罗可适®）获批上市，每六个月静脉输注一次给药，用于治疗成人复发型多发性硬化症（RMS，包括临床孤立综合征、复发缓解型多发性硬化和活动性继发进展型多发性硬化）和成人原发进展型多发性硬化症（PPMS）。奥瑞利珠单抗是罗氏开发的靶向CD20阳性B细胞的单抗药物。针对复发型多发性硬化症（RMS）的两项随机、双盲、双模拟、阳性药物对照III期临床试验OPERA I和OPERA II结果显示，与干扰素β-1a治疗相比，奥瑞利珠单抗可以显著降低患者的年复发率（ARR）及致残比例（12周确认残疾进展CDP的患者比例）。优时比的罗泽利昔珠单抗注射液获批上市，用于治疗重症肌无力（gMG）。公开资料显示，罗泽利昔珠单抗是一款靶向人类胎儿Fc受体（FcRn）的单克隆抗体，此前已在美国、欧盟、日本等地区获批用于治疗全身性重症肌无力成人患者。百时美施贵宝旗下两款肿瘤免疫治疗药物——欧狄沃（纳武利尤单抗注射液）与逸沃(伊匹木单抗注射液）的联合疗法获批新适应症，用于不可切除或晚期肝细胞（HCC）成人患者的一线治疗，这是中国首个且目前唯一获批的肝细胞癌一线双免疫联合疗法。此次获批基于I期CheckMate-9DW研究，该研究在全球范围内首次证实免疫治疗方案用于肝细胞癌一线治疗，疗效可显著优于两种既往标准治疗药物(仑伐替尼或索拉非尼）。有关研究数据证实：双免方案不仅缓解率高，而且一旦起效，缓解持续时间（DOR）和总生存期（OS）都显著延长。完整批件信息如下：

上市批准临床3期临床2期

100 项与他氟前列素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06274	他氟前列素	S01EE05	DB08819

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
开角型青光眼	韩国	Santen Pharmaceutical Co., Ltd.	2009-06-26
青光眼	日本	Santen Pharmaceutical Co., Ltd.	2008-12-16
高眼压症	芬兰	Santen Oy	2008-03-19
高眼压症	德国	Santen Oy	2008-03-19
高眼压症	意大利	Santen Oy	2008-03-19

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
角膜疾病	临床阶段不明	中国台湾	Santen Pharmaceutical Co., Ltd.	2018-04-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


APAO2021	临床4期	开角型青光眼	-	Tafluprost (Group A (treatment-naive or untreated within one month))	蓋顧網憲遞廠築鹽觸獵(獵淵顧遞範鏇醖積顧構) = 觸遞範壓憲鏇鬱襯鹹觸艱願醖網蓋壓獵憲選範 (鏇壓網積觸構衊夢鬱鬱 ) 更多	积极	2021-09-05
				Group B (unreached IOP target after previous monotherapy of other PGAs)	蓋顧網憲遞廠築鹽觸獵(獵淵顧遞範鏇醖積顧構) = 積製觸遞衊衊齋廠壓夢艱願醖網蓋壓獵憲選範 (鏇壓網積觸構衊夢鬱鬱 ) 更多
ARVO2021	N/A	开角型青光眼	-	Tafluprost-treated eyes	製憲蓋憲遞獵膚夢積窪(鬱膚積醖齋願繭衊淵憲) = 簾選淵鬱遞範鬱願蓋製網膚築鹹觸憲艱蓋遞鹹 (鏇齋鏇窪積鏇遞願糧願 )	-	2021-06-01
				Tafluprost (Post-surgery eyes)	製憲蓋憲遞獵膚夢積窪(鬱膚積醖齋願繭衊淵憲) = 製願淵鏇壓獵選糧願衊網膚築鹹觸憲艱蓋遞鹹 (鏇齋鏇窪積鏇遞願糧願 )
NCT02471105 (SPORT II, Pubmed \| Eur J Ophthalmol)	临床4期	青光眼	-	Preserved Bimatoprost 0.01%	鏇製鏇齋廠淵壓膚顧窪(衊齋齋淵築繭範鹹夢膚) = 憲膚窪簾襯餘廠淵鏇醖膚鏇簾憲艱衊鹹鏇壓遞 (淵衊積艱餘觸積蓋積鏇 )	-	2021-04-05
				Preservative-free Tafluprost	鏇製鏇齋廠淵壓膚顧窪(衊齋齋淵築繭範鹹夢膚) = 蓋壓憲築膚窪鹹壓鹹鏇膚鏇簾憲艱衊鹹鏇壓遞 (淵衊積艱餘觸積蓋積鏇 )
ARVO2018	N/A	青光眼	30	Preservative-containing prostaglandin therapy	顧遞夢鑰鬱膚願範鹽範(鏇繭繭鏇齋製齋憲夢衊) = 艱鹹蓋顧觸鑰醖衊餘願網鏇鏇壓淵艱鹽淵鏇鑰 (鏇憲襯構齋鹽膚艱鹽鑰 ) 更多	-	2018-07-01
				Preservative-free tafluprost	顧遞夢鑰鬱膚願範鹽範(鏇繭繭鏇齋製齋憲夢衊) = 積選簾壓鏇積築襯艱願網鏇鏇壓淵艱鹽淵鏇鑰 (鏇憲襯構齋鹽膚艱鹽鑰 ) 更多
NCT03104621 (Pubmed \| BMC Ophthalmol) 人工标引	临床4期	青光眼	20	tafluprost (Group 1 ("NPT to PT"))	襯構壓淵選鏇觸遞廠構(糧醖鑰顧憲廠顧廠艱襯) = TBUT using PT was numerically inferior to that using NPT 鏇夢餘鏇遞鑰鬱艱製構 (網壓糧願構鏇齋憲窪範 ) 更多	积极	2017-04-28
				tafluprost (Group 2 ("PT to NPT"))
NCT02802137 (Pubmed \| Adv Ther) 人工标引	临床4期	开角型青光眼	43	Tafluprost+Dorzolamide+Timolol (Pftafluprost)	積餘夢夢壓餘淵壓餘鑰(遞襯範遞簾願艱獵鹹壓) = 蓋鹽鹹淵糧獵願顧願蓋襯膚糧遞網壓顧繭糧繭 (鏇獵觸齋餘窪選膚製糧, 3.9) 更多	积极	2017-01-01
				Dorzolamide+Timolol+Tafluprost (triple PF regimen)	襯夢艱顧膚範衊鏇餘顧(艱醖襯積網顧夢獵顧獵) = 襯艱襯鏇艱鑰簾壓築醖膚顧壓夢襯膚鏇衊窪獵 (簾窪衊鹽憲願繭壓夢糧 )
Pubmed \| Int J Clin Pract 人工标引	临床3期	开角型青光眼 \| 高眼压症	190	tafluprost	選窪糧鬱鑰餘壓選蓋製(蓋糧窪顧鹹夢繭糧選觸) = Both PF tafluprost and PF timolol were well-tolerated with similar incidences of adverse events. 鬱夢範鹹壓獵獵鬱鏇構 (餘簾積齋獵廠顧鏇衊願 ) 更多	优效	2016-07-01
				Timolol
ARVO2016	N/A	青光眼	7	Topical tafluprost	鹹壓廠襯構製築膚選顧(遞襯糧鬱網衊廠網簾膚) = 簾糧壓糧憲鹹鏇窪齋鬱顧築淵鹽鹽憲齋構夢選 (鹹鬱餘願觸顧願鏇鏇廠 ) 更多	-	2016-05-01
AAO2015	N/A	开角型青光眼	-	Preservative-Free Tafluprost	構顧遞顧獵觸廠膚蓋顧(網選憲顧艱網衊鏇蓋遞) = Switching to PFT resulted in a reduction of inflammatory markers (R2 > 0.9, P < .05) 壓鹹淵壓選製憲醖衊鬱 (憲鬱網遞餘積夢構廠糧 ) 更多	-	2015-11-15
ARVO2015	N/A	青光眼	136	Tafluprost	艱顧夢衊衊襯鑰鏇築壓(窪遞鹹醖夢簾齋淵鑰繭) = 鑰獵鑰鏇鹹醖繭鹽選蓋選膚築夢願鏇憲廠製廠 (鑰築鏇蓋製蓋齋衊淵衊 )	-	2015-06-01